Page last updated: 2024-12-11
fluticasone furoate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
fluticasone furoate: a glucocorticoid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
fluticasone furoate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a 2-furoyl substituent at position 17. Used in combination with vilanterol trifenate for treatment of bronchospasm associated with chronic obstructive pulmonary disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9854489 |
| CHEMBL ID | 1676 |
| CHEBI ID | 74899 |
| SCHEMBL ID | 140504 |
| MeSH ID | M0514058 |
Synonyms (86)
| Synonym |
|---|
| (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-difluoro-17-{[(fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-16-methyl-3-oxoan drosta-1,4-dien-17-yl furan-2-carboxylate |
| gw6 , |
| veramyst |
| avamys |
| fluticasone furoate |
| allermist |
| gw-685698x |
| gw-685698 |
| 397864-44-7 |
| veramyst (tn) |
| fluticasone furoate (jan/usan/inn) |
| D06315 |
| (6alpha,11beta,16alpha,17alpha)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate |
| 6alpha,9-difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate |
| gw 685698x |
| androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2- furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, s-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)- |
| gw685698x |
| gsk 685 698 |
| gsk685968 |
| gsk-685968 |
| CHEMBL1676 |
| furamist |
| ennhale |
| chebi:74899 , |
| arnuity ellipta |
| flonase sensimist allergy relief |
| fluticasone furoate [usan:inn] |
| androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2- furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, s-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)- |
| unii-js86977wnv |
| flonase sensimist |
| js86977wnv , |
| alisade |
| gsk 685698 |
| bdbm50354851 |
| fluticasonum furoas |
| furoato de fluticasona |
| furoate de fluticasone |
| 6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate |
| fluticasone furoate component of arnuity ellipta |
| fluticasone furoate [usan] |
| (6.alpha.,11.beta.,16.alpha.,17.alpha.)-6,9-difluoro-17-(((fluoro-methyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate |
| breo ellipta component fluticasone furoate |
| (6.alpha.,11.beta.,16.alpha.,17.alpha.)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furoate |
| fluticasone furoate component of trelegy ellipta |
| trelegy ellipta component fluticasone furoate |
| fluticasone furoate [vandf] |
| fluticasone furoate [jan] |
| fluticasone furoate [who-dd] |
| fluticasone furoate [ema epar] |
| 6alpha,9-difluoro-17-[[(fluoromethyl)sulfanyl]carbonyl]-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate |
| (6.alpha.,11.beta.,16.alpha.,17.alpha.)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate |
| fluticasone furoate [mi] |
| fluticasone furoate component of breo ellipta |
| arnuity ellipta component fluticasone furoate |
| fluticasone furoate [inn] |
| androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, s-(fluoromethyl) ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- |
| fluticasone furoate [mart.] |
| fluticasone furoate [orange book] |
| S6487 |
| DB08906 |
| SCHEMBL140504 |
| [(6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate |
| gw685698 |
| (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-difluoro-17-{[(fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-16-methyl-3-oxoan |
| drosta-1,4-dien-17-yl furan-2-carboxylate |
| (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-difluoro-17-{[(fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl furan-2-carboxylate |
| avamys pound>> veramyst pound>> allermist |
| BCP18136 |
| HY-15234 |
| Q2166700 |
| gtpl10892 |
| CS-0003822 |
| (6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate |
| MS-29934 |
| DTXSID401024827 |
| EN300-19659651 |
| (1r,2r,3as,3bs,5s,9as,9br,10s,11as)-5,9b-difluoro-1-{[(fluoromethyl)sulfanyl]carbonyl}-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl furan-2-carboxylate |
| E86983 |
| AKOS040744839 |
| (6alpha,11beta,16alpha,17alpha)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furoate |
| fluticasone furoate (mart.) |
| 6alpha,9-difluoro-17beta-((fluoromethylsulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate |
| (6alpha,11beta,16alpha,17alpha)-6,9-difluoro-17-(((fluoro-methyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate |
| 6alpha,9-difluoro-17beta-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate |
| androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, s-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)- |
| flonase sensimistallergy relief |
Research Excerpts
Overview
Fluticasone furoate (FF) is an intranasal corticosteroid indicated for the treatment of allergic rhinitis (AR) It has been shown to improve lung function vs. placebo. Fluticas one furoates is a novel, once-daily ICS asthma therapy.
Toxicity
Safety data from 10 parallel-group, randomised, double-blind Phase II and III studies. No dose-response relationship was observed for the overall incidence of adverse events. There were no significant effects of fluticasone furoate on hypothalamic-pituitary-adrenal axis function.
Pharmacokinetics
Population pharmacokinetic (PK) methods were used to characterize the PK of fluticasone furoate (FF) and vilanterol (VI) in patients with asthma following onc.
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β2 agonist vilanterol (VI) is in development for asthma and chronic obstructive pulmonary disease." | ( Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. Andersen, L; Apoux, L; Bateman, ED; Bleecker, ER; Busse, WW; Crawford, J; Hicks, W; Jacques, L; Lötvall, J; O'Byrne, PM; Woodcock, A, 2013) | 0.93 |
Bioavailability
Fluticasone furoate is a recently approved, enhanced- affinity intranasal corticosteroid with low systemic bioavailability. It has proven efficacy in treating allergic rhinitis.
Dosage Studied
Fluticasone furoate (FF) is a new inhaled corticosteroid (ICS) suitable for once-daily dosing in asthma. This article reviews efficacy versus systemic activity profiles for various adherence patterns and dosing regimens.
| Excerpt | Relevance | Reference |
|---|---|---|
| " At the end of the crossover dosing and after completion of the attributes questionnaires, preference for individual attributes of FF or FP nasal spray and overall patient preference were evaluated in a third questionnaire that asked "Based on these attributes, which product did you prefer overall?" Additionally, a follow-up phone call was conducted 24 hours after the study to assess any adverse events following study treatment." | ( Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Dalal, AA; Leflein, J; Lim, J; Meltzer, EO; Meltzer, S; Philpot, EE; Prillaman, BA; Stahlman, JE, 2008) | 0.57 |
| "2% ophthalmic solution, fluticasone furoate nasal spray, a tear substitute, or saline nasal spray), dosed with study medication, and challenged 15 minutes later, after which ocular allergic signs and symptoms were assessed." | ( A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Abelson, MB; Gomes, PJ; Kennedy, K; Mahr, T; Rosenwasser, LJ, ) | 0.68 |
| " There was no dose-response relationship across the FF doses studied." | ( Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Bateman, ED; Bleecker, ER; Busse, WW; Davis, AM; Forth, R; Haumann, B; Jacques, L; Lötvall, J; Woodcock, A, 2012) | 1.82 |
| "A dose-response effect was observed for once-daily FF 25-200 μg including (p < 0." | ( Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Bateman, ED; Bleecker, ER; Busse, WW; Davis, AM; Forth, R; Haumann, B; Jacques, L; Lötvall, J; Medley, H; Woodcock, A, 2012) | 0.68 |
| " Results from Phase II studies have shown clinically and statistically significant improvements over placebo in trough (24-hour postdose) forced expiratory volume in 1 second (FEV(1)) after once-daily dosing with FF or VI (VI concurrently with an inhaled corticosteroid) in asthma and VI in COPD." | ( Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Boscia, JA; Crim, C; Pudi, KK; Sanford, L; Siederer, SK; Zvarich, MT, 2012) | 0.7 |
| "Patients (aged ≥40 years) who completed a 2-week placebo run-in period were randomized to 1 of 18 three-course sequences of placebo and 2 of 3 dose combinations of FF/VI (50/25 μg, 100/25 μg, and 200/25 μg), dosed once daily in the morning." | ( Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Boscia, JA; Crim, C; Pudi, KK; Sanford, L; Siederer, SK; Zvarich, MT, 2012) | 0.7 |
| " However, morning trough values might have been affected by higher placebo response after morning dosing (18." | ( Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Allen, A; Medley, H; Orozco, S, 2012) | 0.66 |
| " There was no evidence of a dose-response relationship between FF doses." | ( Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Bateman, ED; Bleecker, ER; Busse, WW; Davis, AM; Frith, L; Haumann, B; House, KW; Jacques, L; Lötvall, J; Woodcock, A, 2012) | 0.77 |
| " This would suggest that FF is exhibiting absorption rate-limited pharmacokinetics following inhaled FF dosing and that the apparent t(½β) is an estimate of absorption rate." | ( Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Allen, A; Bareille, PJ; Rousell, VM, 2013) | 1.83 |
| " Peak plasma concentration of FF and VI following repeat dosing was up to two times higher compared with the single dose." | ( The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Allen, A; Hirama, T; Kempsford, R; Nakahara, N; Nohda, S; Wakamatsu, A; Yamada, M, 2013) | 0.62 |
| "In healthy Japanese subjects, no safety concerns were found following repeat dosing of FF and VI or single dosing of FF, VI and FF/VI." | ( The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Allen, A; Hirama, T; Kempsford, R; Nakahara, N; Nohda, S; Wakamatsu, A; Yamada, M, 2013) | 0.62 |
| "Repeat once-daily dosing of FF/VI (200/25 μg), which is the highest therapeutic strength used in phase III studies, is not associated with QTc prolongation in healthy subjects." | ( A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects. Allen, A; Crim, C; Kelly, K; Kempsford, R; Saggu, P, 2014) | 0.67 |
| " Higher FF systemic exposure was seen following inhaled dosing in Chinese, Japanese and Korean subjects compared with Caucasian subjects." | ( Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. Allen, A; Bal, J; Cheesbrough, A; Hamilton, M; Kempsford, R, 2014) | 0.64 |
| "Modestly higher (<50%) FF systemic exposure seen in East Asian subjects following inhaled dosing was not associated with a clinically significant effect on serum cortisol, suggesting that a clinical dose adjustment in East Asian subjects is not required." | ( Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. Allen, A; Bal, J; Cheesbrough, A; Hamilton, M; Kempsford, R, 2014) | 0.64 |
| "To investigate the effect of time of day of dosing (morning or evening) on lung function following administration of fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg." | ( The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Bal, J; Kempsford, RD; Oliver, A; Quinn, D; Tombs, L, 2013) | 0.9 |
| "FF/VI 100/25 administered morning or evening produced clinically significant increases in weighted mean FEV1: the differences [95% confidence interval (CI)] from placebo were 377 mL [293, 462] and 422 mL [337, 507], respectively; the difference between morning and evening dosing was -44 mL [-125, 36]." | ( The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Bal, J; Kempsford, RD; Oliver, A; Quinn, D; Tombs, L, 2013) | 0.69 |
| "FF/VI 100/25 produces comparable improvements in lung function whether dosed in the morning or evening in subjects with persistent asthma." | ( The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Bal, J; Kempsford, RD; Oliver, A; Quinn, D; Tombs, L, 2013) | 0.69 |
| " The once-daily dosing might improve adherence in select patients." | ( Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Bollmeier, SG; Prosser, TR, 2014) | 0.76 |
| "Once-daily repeated dosing of FF/VI, 100/25 µg, using the ELLIPTA dry powder inhaler was as well tolerated as FF, 100 µg, in this small, selected population of 5- to 11-year-old, mostly white/caucasian children with persistent asthma." | ( Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Allen, A; Hamilton, M; Inamdar, A; Kempsford, R; Oliver, A; Tombs, L; VanBuren, S, 2014) | 0.75 |
| " Fluticasone furoate (FF) is a new inhaled corticosteroid (ICS) suitable for once-daily dosing in asthma." | ( Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. Bateman, ED; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Stone, S; Woodcock, A, 2014) | 1.62 |
| " Three hundred and fifty-one patients (aged ≥12 years; uncontrolled by non-ICS therapy) were randomized to treatment (1 : 1 : 1) with once-daily FF 50 mcg dosed in the evening, twice-daily fluticasone propionate (FP) 100 mcg or placebo." | ( Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. Bateman, ED; Busse, WW; Forth, R; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2014) | 0.79 |
| "We evaluated the dose-response of umeclidinium (UMEC; a long-acting muscarinic antagonist) combined with fluticasone furoate (FF; an inhaled corticosteroid [ICS]) in patients with asthma." | ( The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Edwards, LD; Kerwin, E; Lee, LA; Pascoe, S; Trivedi, R; Yang, S, 2015) | 0.99 |
| "Fluticasone furoate/vilanterol (FF/VI) is a novel inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) fixed dose combination that, by simplifying the dosing schedule, allows, for the first time in a member of the ICS/LABA class, a shift from twice-daily to once-daily treatment." | ( Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. Capuano, A; Cazzola, M; Matera, MG, 2015) | 3.3 |
| " The present study aimed to further characterise the UMEC dose-response relationship with change from baseline trough forced expiratory volume in one second (FEV1) (day 15)." | ( Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma. Beerahee, M; Goyal, N; Lee, L; Pascoe, S; Trivedi, R; Yang, S, 2015) | 0.68 |
| "Within the Study 1 dose range, no significant dose-response was demonstrated." | ( Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma. Beerahee, M; Goyal, N; Lee, L; Pascoe, S; Trivedi, R; Yang, S, 2015) | 0.68 |
| " FF/VI, by simplifying the dosing schedule, allows, for the first time, a shift from twice-daily to once-daily treatment, with an acceptable safety and tolerability profile that is consistent with the ICS/LABA class." | ( Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. Cazzola, M; Matera, MG; Rogliani, P, 2015) | 1.86 |
| " The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence." | ( The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience. Albertson, TE; Richards, JR; Zeki, AA, 2016) | 0.76 |
| " One of the newer fluticasone furoate studies overcomes these limitations and also provides an assessment of a range of doses, suggesting that the therapeutic window is quite narrow and that conventional dosing has probably been too high, although the absolute risk may be different compared to other drugs." | ( Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review. Iannella, H; Luna, C; Waterer, G, 2016) | 0.77 |
| " The effect of race on PK of FF or VI does not have impact on dosage adjustments for FF/VI in East Asian patients with asthma." | ( Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma. Allen, A; Siederer, S; Yang, S, 2016) | 0.7 |
| " It is hoped that OD dosage of FF/VI can improve adherence and hence asthma control in these patients, however evidence to support this has yet to become available." | ( Fluticasone furoate and vilanterol trifenatate combination therapy for the treatment of asthma. Chang, V; Gray, EL; Thomas, PS, 2016) | 1.88 |
| " In the integrated analysis, no dose-response relationship was observed for the overall incidence of adverse events and there were no significant effects of fluticasone furoate on hypothalamic-pituitary-adrenal axis function." | ( Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Busse, WW; Goldfrad, C; Jacques, L; Kwon, N; O'Byrne, PM; Perrio, M; Yates, LJ, 2016) | 0.88 |
| " To encourage patient adherence, two classes of medication are often combined in a single medication device; it seems that once-daily dosing offers greatest convenience to patients and may markedly influence adherence." | ( Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Bala, MM; Gross-Sondej, I; Jankowski, M; Nowobilski, R; Sliwka, A; Storman, M, 2018) | 0.48 |
| " The inhibition in AHR after one week of daily dosing coincided with a significant decrease in FeNO at 7 days." | ( Short-term effect of once-daily fluticasone furoate on methacholine-induced bronchoconstriction in mild asthmatics. Blais, CM; Cockcroft, DW; Davis, BE; Okonkwo, CS, 2019) | 0.8 |
| " Low plasma concentrations of 6β-hydroxy mometasone were detected after intravenous dosing (Study 1) and after multiple inhaled dosing (Study 2); mometasone was not detected in any samples." | ( Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Daley-Yates, PT; Deans, A; Mehta, R; Sousa, AR, 2022) | 0.95 |
| " Repeat dosing of inhaled MF and FP in the therapeutic range (800 μg/day) resulted in greater systemic exposure for MF, and a 35% reduction in serum cortisol that was 2-fold greater than for FP." | ( Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Daley-Yates, PT; Deans, A; Mehta, R; Sousa, AR, 2022) | 0.95 |
| " This article reviews efficacy versus systemic activity profiles for various adherence patterns and dosing regimens of fluticasone furoate (FF)-containing and budesonide (BUD)-containing asthma therapies in clinical trials and real-world studies." | ( Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management. Berend, N; Daley-Yates, P; Igea, JM; Macchia, L; Plank, M; Singh, D; Verma, M, 2023) | 1.34 |
| "We performed a structured literature review (1 January 2000-3 March 2022) and mathematical modelling analysis of FF-containing and BUD-containing regular daily dosing in patients with mild-to-severe asthma, as-needed BUD/formoterol (FOR) in mild asthma, and BUD/FOR maintenance and reliever therapy (MART) dosing in moderate-to-severe asthma, to assess efficacy (bronchoprotection) and systemic activity (cortisol suppression) profiles of dosing patterns of ICS use in multiple adherence scenarios." | ( Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management. Berend, N; Daley-Yates, P; Igea, JM; Macchia, L; Plank, M; Singh, D; Verma, M, 2023) | 1.13 |
| " Focusing on FF-containing or BUD-containing treatments at comparable adherence rates, regular daily FF or FF/vilanterol (VI) dosing provided more prolonged bronchoprotection and fewer systemic effects than daily BUD, daily BUD/FOR, or BUD/FOR MART dosing, especially in low adherence scenarios." | ( Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management. Berend, N; Daley-Yates, P; Igea, JM; Macchia, L; Plank, M; Singh, D; Verma, M, 2023) | 1.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (3)
| Role | Description |
|---|---|
| anti-allergic agent | A drug used to treat allergic reactions. |
| prodrug | A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. |
| anti-asthmatic drug | A drug used to treat asthma. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (7)
| Class | Description |
|---|---|
| 11beta-hydroxy steroid | Any 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration. |
| corticosteroid | A natural or synthetic analogue of the hormones secreted by the adrenal gland. |
| fluorinated steroid | A steroid which is substituted with one or more fluorine atoms in any position. |
| steroid ester | |
| 2-furoate ester | Any carboxylic ester where the carboxylic acid component is 2-furoic acid. |
| thioester | A compound of general formula RC(=O)SR'. Compare with thionoester, RC(=S)OR'. |
| 3-oxo-Delta(1),Delta(4)-steroid | A 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (6)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | IC50 (µMol) | 5.0000 | 0.0000 | 0.7237 | 32.7000 | AID1476014 |
| Glucocorticoid receptor | Homo sapiens (human) | IC50 (µMol) | 0.0004 | 0.0000 | 0.4953 | 10.0000 | AID1476013; AID429130 |
| Glucocorticoid receptor | Homo sapiens (human) | Ki | 0.0005 | 0.0001 | 0.3863 | 7.0010 | AID1375646 |
| Progesterone receptor | Homo sapiens (human) | IC50 (µMol) | 0.0210 | 0.0000 | 0.5807 | 10.0000 | AID1476016 |
| Mineralocorticoid receptor | Homo sapiens (human) | IC50 (µMol) | 0.1660 | 0.0003 | 0.7484 | 10.0000 | AID1476011 |
| Androgen receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.8800 | 0.0010 | 1.9794 | 14.1600 | AID1476012 |
| Estrogen receptor beta | Homo sapiens (human) | IC50 (µMol) | 5.0000 | 0.0001 | 0.5294 | 32.7000 | AID1476015 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glucocorticoid receptor | Homo sapiens (human) | EC50 (µMol) | 0.0004 | 0.0004 | 0.0540 | 1.0000 | AID1375648; AID622345 |
| Mineralocorticoid receptor | Homo sapiens (human) | EC50 (µMol) | 3.0000 | 0.0000 | 0.0126 | 0.1000 | AID1375650 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (81)
Molecular Functions (37)
Ceullar Components (21)
Bioassays (28)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID429130 | Agonist activity at GR in human A549 cells by NF-kappaB transrepression assay | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16 | Highly tractable, sub-nanomolar non-steroidal glucocorticoid receptor agonists. |
| AID1375648 | Induction of nuclear translocation of human recombinant ProLabel-tagged glucocorticoid receptor expressed in CHO-K1 cells after 3 hrs by luminescence method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID1476013 | Displacement of fluormone labelled GS Red from human recombinant glucocorticoid receptor after 2 hrs by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20 | Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases. |
| AID1375657 | MRTlast in Sprague-Dawley rat plasma at 1 umol/kg, it by HPLC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID1068841 | n-Octanol-buffer partition coefficient, log D of the compound at pH 7.4 by shake-flask method | 2014 | Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3 | Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases. |
| AID1375652 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release preincubated for 15 mins followed by LPS challenge measured after 18 hrs by Griess assay | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID1476016 | Displacement of fluormone labelled PL Red from human recombinant progesterone receptor after 1 to 6 hrs ligand by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20 | Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases. |
| AID1375654 | Cmax in Sprague-Dawley rat lung at 1 umol/kg, it by HPLC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID1476014 | Displacement of fluormone labelled EL Red from human recombinant estrogen receptor alpha after 1 to 5 hrs by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20 | Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases. |
| AID1476015 | Displacement of fluormone labelled EL Red from human recombinant estrogen receptor beta after 1 to 5 hrs by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20 | Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases. |
| AID1375653 | Cmax in Sprague-Dawley rat plasma at 1 umol/kg, it by HPLC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID622346 | Inhibition of TNFalpha release in human PBMC by ELISA assay | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19 | Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma. |
| AID1375650 | Induction of nuclear translocation of human recombinant ProLabel-tagged mineralocorticoid receptor expressed in CHO-K1 cells after 3 hrs by luminescence method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID1476012 | Displacement of fluormone labelled AL green from rat recombinant His/GST-tagged androgen receptor LBD after 4 to 6 hrs by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20 | Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases. |
| AID1476011 | Displacement of [3H]-aldosterone from N terminal maltose binding protein tagged human mineralocorticoid receptor LBD (726 to 984 residues) expressed in baculovirus infected high five cells after 8 hrs by scintillation proximity assay | 2017 | Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20 | Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases. |
| AID1375651 | Selectivity ratio of EC50 for human recombinant ProLabel-tagged mineralocorticoid receptor to EC50 for human recombinant ProLabel-tagged glucocorticoid receptor | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID1654621 | Volume of distribution in human at 0.25 mg, iv administered as single dose measured up to 168 hrs | 2020 | Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12 | Metabolic and Pharmaceutical Aspects of Fluorinated Compounds. |
| AID622347 | Inhibition of TNFalpha release in LPS-stimulated human whole blood by ELISA assay | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19 | Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma. |
| AID1654620 | Half life in human at 0.25 mg, iv administered as single dose measured up to 168 hrs | 2020 | Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12 | Metabolic and Pharmaceutical Aspects of Fluorinated Compounds. |
| AID622345 | Agonist activity at GR in human SW1353 cells transfected with luciferase gene linked to MMTV promoter assessed as luciferase transactivation activity | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19 | Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma. |
| AID1068810 | Inhibition of ovalbumin-induced lung eosinophilia in Dunkin-Hartley guinea pig at 0.3 umol/kg administered intratracheally 2 hrs before ovalbumin challenge | 2014 | Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3 | Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases. |
| AID1375655 | AUClast in Sprague-Dawley rat plasma at 1 umol/kg, it by HPLC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID1375656 | AUClast in Sprague-Dawley rat lung at 1 umol/kg, it by HPLC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID1375646 | Displacement of [3H]dexamethasone from human recombinant glucocorticoid receptor expressed in insect cells after 24 hrs by scintillation proximity assay | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID1375658 | MRTlast in Sprague-Dawley rat lung at 1 umol/kg, it by HPLC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| AID404878 | Displacement of [3H]Dexamethasone from glucocorticoid receptor in human lung tissue relative to Dexamethasone | 2008 | Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12 | X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. |
| AID1654622 | Oral bioavailability in human at 2 mg administered as single dose and measured up to 168 hrs | 2020 | Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12 | Metabolic and Pharmaceutical Aspects of Fluorinated Compounds. |
| AID1375665 | Antiinflammatory activity in LPS-induced Sprague-Dawley rat neutrophilic lung inflammation model assessed as inhibition of neutrophilic infiltration in bronchoalveolar lavage at ID80, it preincubated for 24 hrs followed by LPS challenge measured after 4 h | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (232)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (10.78) | 29.6817 |
| 2010's | 169 (72.84) | 24.3611 |
| 2020's | 38 (16.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 53.98
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (53.98) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 134 (53.17%) | 5.53% |
| Reviews | 37 (14.68%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 2 (0.79%) | 0.25% |
| Other | 79 (31.35%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||